{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein plays a central role in the pathogenesis of Parkinson's disease (PD), as evidenced by the identification of single point mutations and gene duplication/triplication that are causally linked to early-onset familial PD, as well as its conspicuous aggregation in filamentous inclusions associated with PD and other a-synucleinopathies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the role of a-synuclein in the pathogenesis of Parkinson's disease, linking mutations and aggregation to the disease.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "This study uses single-molecule FRET (smFRET) and ensemble (far-UV CD) measurements to probe the effects of mutations on the coupled binding and folding of a-synuclein, which relates to its aggregation properties and membrane interactions.",
          "judgment": "Yes",
          "reasoning": "The assay assesses the folding and binding properties of a-synuclein, which is directly relevant to its aggregation and function in PD, thus effectively modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type (WT) a-synuclein as a normal/negative control. Multiple replicates were likely used as the CD experiments and smFRET experiments generate statistical data, although the exact number of replicates is not explicitly stated.",
          "judgment": "No",
          "reasoning": "While a normal/negative control (WT) was used, the paper does not explicitly state the use of an abnormal/positive/null control, nor does it explicitly state the number of replicates used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper states 'We carried out smFRET experiments with a home-built microscope system described previously' and cites their previous publication (ref 16).",
          "judgment": "Yes",
          "reasoning": "The smFRET assay was described in a previous publication and thus considered validated.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant was shown to have altered folding properties in smFRET and CD assays compared to WT, favoring the bent helical structure.  The study uses a previously validated smFRET assay. Due to insufficient controls/replicates in this specific instance, the strength is capped at PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein plays a central role in the pathogenesis of Parkinson's disease (PD), as evidenced by the identification of single point mutations and gene duplication/triplication that are causally linked to early-onset familial PD, as well as its conspicuous aggregation in filamentous inclusions associated with PD and other a-synucleinopathies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the role of a-synuclein in the pathogenesis of Parkinson's disease, linking mutations and aggregation to the disease.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "This study uses single-molecule FRET (smFRET) and ensemble (far-UV CD) measurements to probe the effects of mutations on the coupled binding and folding of a-synuclein, which relates to its aggregation properties and membrane interactions.",
          "judgment": "Yes",
          "reasoning": "The assay assesses the folding and binding properties of a-synuclein, which is directly relevant to its aggregation and function in PD, thus effectively modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type (WT) a-synuclein as a normal/negative control. The paper does not explicitly state the use of an abnormal/positive/null control, nor does it explicitly state the number of replicates used.",
          "judgment": "No",
          "reasoning": "While a normal/negative control (WT) was used, the paper does not explicitly state the use of an abnormal/positive/null control, nor does it explicitly state the number of replicates used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper states 'We carried out smFRET experiments with a home-built microscope system described previously' and cites their previous publication (ref 16).",
          "judgment": "Yes",
          "reasoning": "The smFRET assay was described in a previous publication and thus considered validated.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T mutant was studied, however the functional evidence strength is capped at PS3_supporting due to insufficient controls/replicates in the specific instance, but the study uses a previously validated smFRET assay."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein plays a central role in the pathogenesis of Parkinson's disease (PD), as evidenced by the identification of single point mutations and gene duplication/triplication that are causally linked to early-onset familial PD, as well as its conspicuous aggregation in filamentous inclusions associated with PD and other a-synucleinopathies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the role of a-synuclein in the pathogenesis of Parkinson's disease, linking mutations and aggregation to the disease.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "This study uses single-molecule FRET (smFRET) and ensemble (far-UV CD) measurements to probe the effects of mutations on the coupled binding and folding of a-synuclein, which relates to its aggregation properties and membrane interactions.",
          "judgment": "Yes",
          "reasoning": "The assay assesses the folding and binding properties of a-synuclein, which is directly relevant to its aggregation and function in PD, thus effectively modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included wild-type (WT) a-synuclein as a normal/negative control. The paper does not explicitly state the use of an abnormal/positive/null control, nor does it explicitly state the number of replicates used.",
          "judgment": "No",
          "reasoning": "While a normal/negative control (WT) was used, the paper does not explicitly state the use of an abnormal/positive/null control, nor does it explicitly state the number of replicates used.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper states 'We carried out smFRET experiments with a home-built microscope system described previously' and cites their previous publication (ref 16).",
          "judgment": "Yes",
          "reasoning": "The smFRET assay was described in a previous publication and thus considered validated.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E46K mutant was studied, however the functional evidence strength is capped at PS3_supporting due to insufficient controls/replicates in the specific instance, but the study uses a previously validated smFRET assay."
    }
  ]
}
